From 2011.igem.org

Revision as of 02:03, 29 September 2011

Testing Kumamolisin-As against SC-PEP

After identifying Kumamolisin as a good candidate for activity at low pH, we tested its activity on breaking down PQLP at pH 4 against the activity of SC PEP, the enzyme currently in clinical trials for breaking down gluten. Kumamolisin had never been tested for its ability to breakdown gluten, and so we began novel experimentation into the enzyme's activity on our gluten model. From tests using the fluorescent PQLP system described in our methods section, Kumamolisin showed about 7 times better activity on breaking down PQLP at pH 4 when compared to the activity of SC PEP.

Initial screenings revealed that Kumamolisin has a much higher activity level than SC-PEP, in addition to being amenable to engineering and effective at gastric pH.

Testing mutants for activity on breaking down PQLP

Using a whole cell lysate assay to screen a large number of mutants for good activity

In order to determine whether our proposed mutations to the wild-type Kumamolisin improved the ability of the enzyme to break down PQLP, we screened each mutant with a whole cell lysate fluorescence assay. Cells harboring the expressed mutants were lysed and the assay was performed at pH 4, mimicking the gastric environment. The released enzymes, after being roughly separated from cell material, were added to a fluorescent PQLP that had been conjugated to a quencher. Thus, no fluorescence was achieved until the peptide had been cleaved and the fluorophore had been released from the quencher. This allowed a relative assessment of rate of enzyme activity by measuring increase in fluorescence of the system.

As one might expect, our first screen of mutants showed some mutants with a decrease in activity from the wild-type, some showed no change, and some actually showed great increase in activity. One single point mutant showed over 10-fold increase in activity from wild-type Kumamolisin!

Over 100 unique mutants were screened with a whole cell lysate assay for improved activity on the PQLP model substrate. *"deg" in the data labels indicates use of a degenerate primer. Data for these points is representative of a group of variants, each with different substitutions at one residue. This accounts for the <100 data points on this graph, despite testing >100 novel mutants in total.

Purifying and characterizing promising mutants for accurate rate comparison

Once we had identified mutants that showed a promising increase in activity from the wild-type, we purified and characterized activity in concentration controlled fluorescence assays, identical to the fluorescence system used for the whole cell lysate assay. Our best mutant demonstrated an 11-fold increase in activity from the native enzyme.

Concentration controlled rate data relative to native Kumamolisin for three of our most active mutants.

Combining Mutations for the Construction of a Gluten Hydrolase

In order to achieve even more rate improvement from the native, we repeated our mutagenesis, this time taking successful mutations and adding them together to make combinatorial variants.

Successful mutations were combined to construct a second library for screening

After designing a collection of combinatorial mutants, drawing from successful mutations discovered in the first round, we again performed a rough screen to identify promising combinations of mutations. From the initial screen on our combinatorial mutants, it appeared that we had achieved around 50 times better activity than native Kumamolisin on breaking down PQLP.

From initial whole cell lysate screens on combinatorial mutants, it appears that about 50-fold improvement over native Kumamolisin activity on PQLP has been achieved.

One of the combinatorial mutants resulted in over a 100-fold increase in activity

By combining two of our top groups of mutations from the first round, we achieved an over 100-fold increase in activity on breaking down PQLP from the wild-type enzyme. This variant enzyme is ultimately 784 times better at breaking down PQLP than SC PEP, the enzyme currently in clinical trials for treating gluten intolerance!

Our final engineered enzyme showed activity over 100 fold higher than wild type Kumamolisin, and ~700 fold higher than SC-PEP.